- Study shows once-weekly SOLOSEC may surpass current CDC-recommended BV treatments.
- Recurrent BV affects 21 million U.S. women, with a market projected to reach $1 billion by 2033.
- SOLOSEC's simplified dosing could improve treatment adherence over complex protocols.
At the 2025 ACOG Annual Meeting, Evofem Biosciences (OTCPK: EVFM) unveiled encouraging study results for SOLOSEC (secnidazole) in managing recurrent bacterial vaginosis (BV). The clinical study, which involved 24 women, demonstrated that once-weekly dosing of SOLOSEC 2g oral granules was as effective, if not more so, than the current suppressive treatments recommended by the CDC.
Bacterial vaginosis, which is the leading cause of vaginal discharge among reproductive-age women, impacts approximately 21 million women in the United States. Of these, up to 50% experience a recurrence of the condition within six months post-treatment. The market for BV treatments in the U.S. is expected to expand significantly, potentially reaching $1.0 billion by 2033, driven by increased public health awareness and advancements in diagnostics.
SOLOSEC, currently approved for initial BV treatment in females aged 12 and older, offers a promising once-weekly oral dosing alternative that could alleviate adherence challenges associated with existing treatment regimens. Traditional protocols often require daily oral antibiotics and intravaginal applications, which can be cumbersome for patients to maintain over extended periods.
While SOLOSEC is yet to gain approval for treating recurrent BV, the investigational findings were highlighted by Dr. Chemen M. Neal of Indiana University School of Medicine, who noted the potential for improved patient adherence when using the simplified dosing schedule. The study is set to be submitted to a peer-reviewed journal, marking a step forward in expanding SOLOSEC's indications.
The promising results position SOLOSEC as a potential game-changer in the management of recurrent BV, offering a more user-friendly and potent alternative to complicated existing treatments. Evofem Biosciences is expected to leverage these findings to enhance its presence in the lucrative BV treatment market.
